Expert insights. Personalized for you.
Drugs Related Topics 
Outsourcing Pharma
APRIL 5, 2032
The Australian biotechnology company has been granted ODD status from the agency for Veyonda, a therapy intended for the treatment of soft-tissue sarcoma. Markets & Regulations
World of DTC Marketing
OCTOBER 12, 2021
According to the KFF poll “ most adults – across partisans – don’t believe high drug prices are needed for drug companies to invest in new research instead agreeing that “even if U.S. The post Pharma losing the battle over drug prices.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
NOVEMBER 28, 2022
The company will cut its R&D workforce by 75% and discontinue development of its experimental lung cancer drug poziotinib
Bio Pharma Dive
DECEMBER 6, 2022
The second startup to emerge from Star’s “hub-and-spoke” model aims to develop a Hemlibra-like antibody drug for the blood clotting disorder von Willebrand disease
Bio Pharma Dive
DECEMBER 1, 2022
The drug is currently in mid-stage testing as a treatment for ulcerative colitis. If it continues to advance, it could be the first approved therapy aimed at a protein known as TL1A, a target multiple other companies are pursuing
World of DTC Marketing
MARCH 23, 2022
Accelerated Approval allows for early access to drugs and biologics based on initial evidence of safety and effectiveness, while confirmatory studies required to verify clinical benefits are ongoing. Since then, accelerated Approval has shifted focus to oncology drugs.
Bio Pharma Dive
DECEMBER 5, 2022
After a private equity takeover unraveled this summer, the women’s health company is selling its drug portfolio to Mayne Pharma in a $153 million deal
World of DTC Marketing
JULY 13, 2021
SUMMARY: The FDA has many puzzled as to why they approve some drugs with questionable data and ask for more data on other drugs. The FDA approves drugs on the potential to save a life, the cost of the drugs is never considered in the process.
Bio Pharma Dive
NOVEMBER 9, 2022
The biotech will sell its royalty interest in a heart disease drug Amgen is developing for $250 million, extending its operating runway by several quarters
World of DTC Marketing
JULY 17, 2022
And the Covid-19 pandemic only underscored that obesity puts people at greater risk for infectious disease but are new weight loss drugs the answer? Novo Nordisk more than doubled its sales targets for obesity drugs to $3.7bn by 2025. As I See It Weight Loss Drugs
Bio Pharma Dive
OCTOBER 10, 2022
By taking advantage of pre-filed DMFs, researchers benefit from the value, time savings and reduced complexities of having someone else do the heavy lifting for key components of the final drug product
World of DTC Marketing
JANUARY 28, 2022
When drug makers like Xtandi’s manufacturer, Astellas Pharma, price gouge sick Americans, the U.S. The post Drug company profiteering. A cancer medication called Xtandi costs $189,800 per year and was developed with taxpayer dollars. The U.S.
Elsevier
JUNE 1, 2022
Pharmaceutical drugs can work wonders for patients, whether it’s treating rare diseases or easing everyday maladies. But drugs can also be complex. Also, the longer that a drug is on the market, the more its manufacturer might learn and document about its effects.
Bio Pharma Dive
NOVEMBER 10, 2022
The buzzy startup, which planned to undercut big pharma on price, also dropped plans to seek U.S. approval in lung cancer of an immunotherapy competitor to Keytruda
World of DTC Marketing
SEPTEMBER 7, 2021
While it’s true, the drug industry developed COVID vaccines; the government spent billions on research pre-pandemic and $18 billion more on trials, production, and purchase. Drug corps are reaping record profits. Drug companies should prepare for this scenario.
Bio Pharma Dive
NOVEMBER 29, 2022
At a medical conference, the companies detailed clinical trial results that could help support approval of their drug, lecanemab. However, some doctors aren’t yet convinced the medicine’s risks are worth its potential benefits
Bio Pharma Dive
SEPTEMBER 30, 2022
The biotechnology startup will part with its lead drug candidate, an anti-inflammatory small molecule, in Novo Nordisk’s bet on inflammasome treatments
Bio Pharma Dive
DECEMBER 5, 2022
The positive results could help Novartis secure approval for earlier use of the radiopharmaceutical drug Pluvicto, potentially broadening the number of eligible patients by several times the current market
World of DTC Marketing
DECEMBER 10, 2020
SUMMARY: (JAMA) The median drug wholesale list price (as defined by Average Wholesale Price) increased by 129% from 2010-2016, while median patient out-of-pocket costs increased by 53% and median insurance payments after rebates and discounts increased by 64%. Drug Prices
Bio Pharma Dive
OCTOBER 17, 2022
Beginning a high-stakes advisory meeting, CDER head Patrizia Cavazzoni said that Covis Pharma’s drug is ineffective and should not remain on the market
Bio Pharma Dive
OCTOBER 31, 2022
How flexible API access to integrated 'omics data helps boost agility and speed in drug research
World of DTC Marketing
FEBRUARY 25, 2022
billion on Thursday for allegedly delaying its Breyanzi cancer drug to avoid payments to shareholders of the former Celgene Corp, which the drugmaker bought in 2019. Food and Drug Administration approval for the non-Hodgkin lymphoma drug by a Dec.
Bio Pharma Dive
OCTOBER 10, 2022
The drug could help Merck fill an expected gap in revenue when patents on Keytruda expire Late-stage study results showed sotatercept, which Merck acquired via its Acceleron deal, benefited patients with PAH.
Bio Pharma Dive
OCTOBER 3, 2022
Part of a $1 billion alliance the companies formed in 2020, the drug will be tested in a large study of patients who test positive for mutations in a gene called LRRK2
Bio Pharma Dive
NOVEMBER 7, 2022
The drug, Blenrep, did not outperform a standard treatment in relapsed or refractory multiple myeloma, setting back GSK's plans to confirm the conditional approval it received in 2020
Bio Pharma Dive
NOVEMBER 22, 2022
In an effort to extend its cash runway and keep its stock listing, ObsEva is offloading rights to an experimental preterm labor drug in a deal with Xoma
Bio Pharma Dive
OCTOBER 13, 2022
A $168 million Series B round brings Odyssey’s total funding to date near $400 million, helping the startup support a growing pipeline of cancer and immune disease drug candidates
World of DTC Marketing
JUNE 16, 2021
This includes about one in five who report that they have not filled a prescription or took an over-the counter drug instead, and about one in ten who say they have cut pills in half or skipped a dose. Drug prices in the United States are extreme. Drug Prices
World of DTC Marketing
OCTOBER 6, 2020
This translates to longer development times for cancer drugs which means that cancer patients could suffer. It’s essential that drug companies get creative and find new ways to reach patients when incomes to cancer drug screening and clinical trials.
Bio Pharma Dive
NOVEMBER 28, 2022
The company, one of several developing a drug for treatment-resistant hypertension, had pulled off one of 2022’s top performing biotech IPOs prior to the results
World of DTC Marketing
MARCH 23, 2021
SUMMARY: Democratic lawmakers are weighing whether to include drug pricing measures that could extract tens of billions of dollars from the industry. We’re just not sure when,” said one drug industry lobbying source. The drug industry has had a large target on its back for a long time.
Bio Pharma Dive
DECEMBER 6, 2022
regulators’ recent moves to closely evaluate a class of drugs known as PI3 kinase inhibitors The decision not to run a Phase 3 trial of their medicine is the latest fallout from U.S.
Bio Pharma Dive
SEPTEMBER 14, 2022
The well-funded startup is planning Phase 3 trials for a drug it claims could be superior to top-selling medicines from Novartis and others
Bio Pharma Dive
DECEMBER 7, 2022
Having scored positive results in two key studies for ulcerative colitis and Crohn’s disease, Prometheus now intends to advance the drug, called PRA023, into pivotal testing
Bio Pharma Dive
NOVEMBER 18, 2022
To be sold as Tzield, the drug will cost $193,900 for a typical full regimen Provention Bio’s teplizumab is meant to prevent the onset of Type 1 diabetes.
Bio Pharma Dive
SEPTEMBER 8, 2022
Fuller data from Alnylam’s APOLLO-B trial confirm the success reported by the company last month, but won’t end a debate on the degree of benefit offered by its drug
NY Times
JUNE 28, 2022
Abortion Telemedicine Abortion Drugs Drugs (Pharmaceuticals) Women and Girls Brazil your-feed-healthcareWith Roe v. Wade overturned, states banning abortion are looking to prevent the distribution of abortion medication. Brazil shows the possible consequences.
Bio Pharma Dive
AUGUST 16, 2022
The company has agreed to spend at least $280 million buying back rights to the drug, called Trodelvy, which were sold to Everest Medicines in 2019
World of DTC Marketing
AUGUST 27, 2021
The FDA approved 309 new drugs between 2011 and 2018, 38 per year on average. In 2018, the FDA approved 59 new drugs – an all-time high. The industry loses an average of $40 billion per year on drug development, part of which is due to trial delays.
NY Times
APRIL 22, 2022
Drugs (Pharmaceuticals) Coronavirus (2019-nCoV) Health Insurance and Managed Care Doctors Vaccination and Immunization Paxlovid (Drug) Evusheld (Drug) Pfizer Inc United StatesOnce again, a dysfunctional health care system has hindered our pandemic response.
Bio Pharma Dive
JUNE 1, 2022
Positive Phase 2 results could help boost company executives' arguments that the drug, called deucravacitinib and under FDA review in psoriasis, will become a top-seller
Bio Pharma Dive
NOVEMBER 4, 2022
Competition is increasing behind newly approved drugs from Roche and J&J, while the long-term benefit of gene therapies for chronic blood disorders is being put to the test
Bio Pharma Dive
NOVEMBER 30, 2022
The richly funded drugmaker will cut 15% of its workforce, or about 75 employees, as well as stop work on one of its preclinical research programs
52 
Let's personalize your content